<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04538820</url>
  </required_header>
  <id_info>
    <org_study_id>92/07</org_study_id>
    <nct_id>NCT04538820</nct_id>
  </id_info>
  <brief_title>Dexamethasone Dose for Postoperative Nausea and Vomiting Prophylaxis in Obese Patients</brief_title>
  <official_title>Dexamethasone Dose for Postoperative Nausea and Vomiting Prophylaxis in Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diskapi Yildirim Beyazit Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diskapi Yildirim Beyazit Education and Research Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      compare the effectiveness of different doses of dexamethasone used for postoperative nausea&#xD;
      and vomiting prophylaxis in obese patients and in normal weight patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      compare the effectiveness of different doses of dexamethasone used for postoperative nausea&#xD;
      and vomiting prophylaxis in obese patients.&#xD;
&#xD;
      compare the effectiveness of dexamethasone given in 4 mg and 8 mg doses in obese patients&#xD;
      with 4 mg doses of dexamethasone in normal weight patients.&#xD;
&#xD;
      4 mg iv dexamethasone will be administered to normal weight patients at induction of&#xD;
      anesthesia. This group will be classified as the control group. In obese patients (BMI&gt;30&#xD;
      kg/m2), one group will receive 4 mg dexamethasone and other group will receive 8 mg&#xD;
      dexamethasone at induction.&#xD;
&#xD;
      Patients will receive general anesthesia with volatile anesthetics and tramadol will be&#xD;
      administered IV at the end of surgery.&#xD;
&#xD;
      Postoperative nausea and vomiting, postoperative pain, blood glucose, wound infection, time&#xD;
      to oral intake, hospital stay will be compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative nausea and vomiting (PONV)</measure>
    <time_frame>PONV scores wİll be record during the ﬁrst 24 hours</time_frame>
    <description>The primary outcome is the overall incidence of PONV during the ﬁrst 24 h, deﬁned as any episode of vomiting or nausea.Nausea will be measured using an 11-point verbal rating scale (VRS) running from 0 (no nausea) to 10 (the worst nausea imaginable). We will deﬁne severe PONV as nausea with a score of at least 4 on the VRS, or vomiting.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative pain: 11-point VRS</measure>
    <time_frame>Pain will be assessed during the ﬁrst 24 hours</time_frame>
    <description>Pain intensity will be measured using a simple 11-point VRS running from 0 (no pain) to 10 (unbearable pain), at rest and on mobilisation (asking the patient to cough).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oral intake</measure>
    <time_frame>during the ﬁrst 24 hours</time_frame>
    <description>patients will be asked first oral fluid intake time charge criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood glucose</measure>
    <time_frame>at 6 and 10 hours after administration of dexamethasone</time_frame>
    <description>Fingerprick capillary blood glucose concentrations will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>during the ﬁrst 24 hours</time_frame>
    <description>the time will be recorded when patients are discharged home</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>wound infection</measure>
    <time_frame>postoperative 30th day</time_frame>
    <description>Patients will be telephone on the 30th postoperative day and questioned in terms of wound infection</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with BMI=18.5-24.9 kg/m2 will be received 4 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with BMI&gt;30 kg/m2 will be received 4 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with BMI&gt;30 kg/m2 will be received 8 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 4 mg IV-control</intervention_name>
    <description>dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to normal weight patients.</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 4 mg IV</intervention_name>
    <description>dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients</description>
    <arm_group_label>4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 8 mg IV</intervention_name>
    <description>dexamethasone 8 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients</description>
    <arm_group_label>8 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        High risk patients for postoperative nausea and vomiting:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  No smoking&#xD;
&#xD;
          -  BMI =18.5-24.9 for control group&#xD;
&#xD;
          -  BMI &gt;30 for other groups&#xD;
&#xD;
          -  undergo laparoscopic cholecystectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bahar SAKIZCI UYAR</last_name>
    <phone>5057000240</phone>
    <email>drsakizciuyar@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>DiskapiYBERH</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bahar SAKIZCI UYAR</last_name>
      <email>drsakizciuyar@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diskapi Yildirim Beyazit Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>Bahar SAKIZCI UYAR</investigator_full_name>
    <investigator_title>medical doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

